Laboratory Corporation of America Holdings (LH)
| Previous close | 276.08 |
| Open | 272.77 |
| Bid | 272.67 x 800 |
| Ask | 272.93 x 800 |
| Day's range | 270.42 - 274.19 |
| 52-week range | 212.85 - 317.17 |
| Volume | |
| Avg. volume | 748,474 |
| Market cap | 26.225B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | 9.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Mar 1994 |
| 1y target est | N/A |
- Business Wire
Labcorp to Announce Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022
BURLINGTON, N.C., January 10, 2022--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- Business Wire
Labcorp to Speak Virtually at the 40th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C., January 04, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m. (ET).
- Business Wire
Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services
BURLINGTON, N.C., December 23, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
